"With the strong commercial success we expect from Zingo, we believe it is important to add production capacity beyond what we are building here in the US," said John P. McLaughlin, chief executive officer of Anesiva. "Our new joint venture will create significant additional capacity that will also help us drive down our manufacturing costs, all with only a modest up-front capital investment."
Anesiva will own 49 percent of the joint venture, which will be named Wanbang/Anesiva (Jiangsu) Pharmaceuticals Ltd. The production area will be located at an existing Wanbang facility in the city of XuZhou in Jiangsu province. Following completion of the assembly facility in XuZhou, Anesiva will seek FDA certification of the facility.
Fosun Pharmaceuticals is one of the largest pharmaceutical manufacturing, distribution and retailing organizations in China. With nearly 10,000 employees, the company manufactures and sells genetically engineered medicines, diagnostic products, Chinese prepared medicines, chemical compound medicines, biological chemical products, reagents and medical apparatus.
About Zingo, Recently FDA Approved for the Reduction of Pain Associated with Venous Access Procedures in Children Three to 18 Years of Age
Zingo is a ready-to-use, single-use, needle-free system that delivers
sterile lidocaine powder into the epidermis of the skin and provides
topical, local analgesia in one to three minutes after administration. This
rapid onset, which may be especially useful in pediatric populations and
busy emergency room settings, means the product can be incorporated into a
medical procedure allowing uninterrupted care, an important advantage over
current options. In addition to the hospital setting, Zingo may be used in
physicians' offices and clinical laborat
|SOURCE Anesiva, Inc.|
Copyright©2007 PR Newswire.
All rights reserved